Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery
Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery
The purpose of this study is to investigate potential metabolic effects of resveratrol in
 morbidly obese women undergoing gastric bypass surgery.

 The investigators hypothesize that resveratrol will:

 -  Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion

 -  Decrease hepatic and adipose tissue VLDL-TG uptake

 -  Increase insulin sensitivity

 The investigators will look at changes in:

 -  Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)

 -  VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous
 abdominal adipose tissue, visceral adipose tissue and liver tissue)

 -  Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)

 -  Regulation of liver fat handling

 -  Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)
Inclusion Criteria:

 -  Female

 -  25-60 years

 -  Obesity (BMI > 35 kg/m2)

 -  Have at least one element of the metabolic syndrome either hypertension and/or
 hypercholesterolemia (high triglyceride, low HDL-cholesterol)

 -  Undergoing gastric bypass surgery

 -  Written informed consent

 Exclusion Criteria:

 -  Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart,
 kidney or liver disease)

 -  May have arthrosis or depression

 -  Any present or previous malignancy

 -  History of smoking

 -  Alcohol dependency (more than 14 units of alcohol per week)

 -  Participation in studies with radioactive isotope within the last six months

 -  Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)